Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Schrodinger (SDGR)
NASDAQ:SDGR
Holding SDGR?
Track your performance easily
SDGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.67 - $33.63
Previous CloseN/A
Volume166.74K
Average Volume (3M)585.75K
Market Cap
$1.36B
Enterprise Value$1.07B
Total Cash (Recent Filing)$36.34M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Feb 26, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding63,632,340
10 Day Avg. Volume545,757
30 Day Avg. Volume585,750
Standard Deviation0.20
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.04
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.55
Enterprise Value/Gross Profit7.62
Enterprise Value/Ebitda-6.89
Forecast
1Y Price Target
$28.50Price Target Upside50.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Schrodinger News
PremiumCompany Announcements
Schrödinger Reports Q3 2024 Earnings and New Novartis Collaboration
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsSDGR and partner NVS received regulatory clearance for their previously announced collaboration, triggering a substantial upfront payment.
Market Position And PerformanceSchrödinger, Inc. is positioned for reacceleration in core business growth should new customer adds recover and churn fall with a rebounding biotech funding environment—potentially offsetting a key bear thesis.
Technology And Platform ExpansionThere is an expansion of the company’s technology platform, indicating potential for future growth.
Bears Say
Financial PerformanceQ3 revenues of $35.3 million fell short due to lower drug discovery revenues.
ProfitabilitySoftware gross margin decreased from 76% to 73%, reflecting lower profitability of the predictive toxicology initiative.
RevenueDrug discovery revenue decreased 75% due to accelerated recognition of deferred revenue associated with programs no longer in SDGR’s collaborative portfolio.
---
Ownership Overview
2.52% Insiders
21.19% Mutual Funds
0.07% Other Institutional Investors
50.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SDGR FAQ
What was Schrodinger’s price range in the past 12 months?
Schrodinger lowest stock price was $16.67 and its highest was $33.63 in the past 12 months.
What is Schrodinger’s market cap?
Schrodinger’s market cap is $1.36B.
When is Schrodinger’s upcoming earnings report date?
Schrodinger’s upcoming earnings report date is Feb 26, 2025 which is in 39 days.
How were Schrodinger’s earnings last quarter?
Schrodinger released its earnings results on Nov 12, 2024. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.633 by $0.113.
Is Schrodinger overvalued?
According to Wall Street analysts Schrodinger’s price is currently Undervalued.
Does Schrodinger pay dividends?
Schrodinger does not currently pay dividends.
What is Schrodinger’s EPS estimate?
Schrodinger’s EPS estimate is -0.35.
How many shares outstanding does Schrodinger have?
Schrodinger has 63,632,340 shares outstanding.
What happened to Schrodinger’s price movement after its last earnings report?
Schrodinger reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.633. Following the earnings report the stock price went up 13.869%.
Which hedge fund is a major shareholder of Schrodinger?
Currently, no hedge funds are holding shares in SDGR
---
Schrodinger Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (50.00% Upside)
$28.50 (50.00% Upside)
Blogger Sentiment
Bullish
SDGR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.67%
12-Months-Change
Fundamentals
Return on Equity
-35.06%
Trailing 12-Months
Asset Growth
-15.72%
Trailing 12-Months
Company Description
Schrodinger
Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. Schrödinger was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in August 1990 and is headquartered in New York, NY.
---
SDGR Company Deck
---
SDGR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a significant new collaboration with Novartis, boosting cash reserves and software revenue growth. However, challenges such as a decline in drug discovery revenue, decreased total revenue, and increased operating loss were also noted. The collaboration with Novartis provides a positive outlook for future revenue growth, but current financial challenges balance out the overall sentiment.Read More>---
SDGR Stock 12 Month Forecast
Average Price Target
$28.50
▲(50.00% Upside)
Technical Analysis
Recursion Pharmaceuticals
―
Denali Therapeutics
―
Quanterix
―
Beam Therapeutics
―
Intellia Therapeutics
―
Fate Therapeutics
―
Best Analysts Covering SDGR
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-9.13%
reiterated a buy rating 9 months ago
Copying David Lebowitz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.13% per trade.
---